Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Angina V: Nursing Management01:20

Angina V: Nursing Management

284
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
284
Angina IV: Management01:26

Angina IV: Management

232
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
232
Angina II: Classification01:27

Angina II: Classification

322
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
322
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

197
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
197
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

210
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
210
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 心血管医学と血液学
  5. 心臓病 (心血管疾患を含む)
  6. 安定した胸痛における副循環の役割:プラセボ制御による侵襲的な研究

安定した胸痛における副循環の役割:プラセボ制御による侵襲的な研究

Christopher A Rajkumar1,2, Michael J Foley1,2, Fiyyaz Ahmed-Jushuf1,2

  • 1National Heart and Lung Institute, Imperial College London, London, UK (C.A.R., M.J.F., F.A.-J., S.C., F.A.S., M.M., A.S., S.G., R.P., G.D.C., J.P.H., D.P.F., M.J.S.-S., R.K.A.-L.).

Circulation
|October 27, 2025

関連する実験動画

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.2K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.7K

PubMed で要約を見る

まとめ
この要約は機械生成です。

安定した冠動脈疾患の患者では,冠動脈付近化により,胸痛の強度が著しく低下します. この研究では,不血症の重度ではなく,よりよい副次流が,より少ない心痛と相関し,非線形的な関係を示唆しました.

科学分野:

  • 心臓病科
  • 血管生物学
  • 発血性心臓病

背景:

キーワード:
担保の流通冠動脈疾患安定した胸痛

関連する実験動画

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.8K
Author Spotlight: Enhancing Coronary Artery Revascularization
05:25

Author Spotlight: Enhancing Coronary Artery Revascularization

Published on: September 15, 2023

1.2K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

3.7K
  • 安定した冠動脈疾患の患者は,しばしば,イシュケミアの負担とアンギナの重度の間の断絶を示します.
  • 缺血と副循環と症状の相互作用を調査することは極めて重要です.

研究 の 目的:

  • 安定した冠動脈疾患における缺血,副循環,および胸痛症状の関係を調べる.
  • 漸進的な補足の徴募が 缺血性予備状態と関連しているかどうかを調べる

主な方法:

  • 51人の重度の単血管性冠動脈疾患と胸痛の患者は,圧力線の研究と冠動脈流量準備の評価を受けた.
  • 参加者は制御された気球閉塞とプラセボ膨張を経験し,スマートフォンアプリを通じて毎日症状を追跡しました.
  • 副流量指数は閉塞中に計算され,疼痛の強さはエピソード後に得点されました.

主要な成果:

  • 胸痛の頻度は,イシュケミアの重症度 (フラクショナル・フロー・リザーブまたはインスタント・ウェーブフリー比率) とわずかに相関していた.
  • 低分流量リザーブと即時無波比の値は,より大きな付加流量と強く相関しています.
  • コラテライゼーションの増加 (より高いコラテライゼーションフロー指数) は,報告された痛みの強度の低下と関連していました.

結論:

  • 冠動脈の Kolateralization は,低血圧と関連しており,胸痛の強さを軽減する可能性があります.
  • これらの発見は,冠動脈狭窄症,缺血,胸痛の複雑な非線形関係を説明するのに役立ちます.